Silence Therapeutics plc
SLN
$5.35
-$0.11-2.02%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -70.37% | -99.10% | 1,180.55% | -58.05% | -93.37% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -70.37% | -99.10% | 1,180.55% | -58.05% | -93.37% |
| Cost of Revenue | -97.45% | -98.07% | 57.35% | 77.41% | -5.95% |
| Gross Profit | 105.39% | -99.32% | 4,086.30% | -240.83% | -132.82% |
| SG&A Expenses | -26.79% | 15.81% | 30.94% | 16.13% | 9.47% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -4.30% | 37.73% | 129.36% | 57.04% | -16.80% |
| Operating Income | 1.88% | -733.77% | 209.44% | -82.40% | -44.03% |
| Income Before Tax | -40.03% | -1,279.59% | 334.35% | -190.74% | -29.89% |
| Income Tax Expenses | -95.61% | -- | -2.40% | -34.11% | 111.32% |
| Earnings from Continuing Operations | -38.47% | -1,134.00% | 159.17% | -236.52% | -51.74% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -38.47% | -1,134.00% | 159.17% | -236.52% | -51.74% |
| EBIT | 1.88% | -733.77% | 209.44% | -82.40% | -44.03% |
| EBITDA | 1.88% | -772.26% | 214.46% | -83.28% | -44.48% |
| EPS Basic | -37.00% | -1,048.48% | 148.75% | -166.71% | -17.42% |
| Normalized Basic EPS | -31.87% | -1,184.35% | 293.13% | -130.47% | -0.50% |
| EPS Diluted | -37.00% | -1,048.48% | 148.75% | -166.71% | -17.42% |
| Normalized Diluted EPS | -31.87% | -1,184.35% | 293.13% | -130.47% | -0.50% |
| Average Basic Shares Outstanding | 1.06% | 7.43% | 21.34% | 26.16% | 29.24% |
| Average Diluted Shares Outstanding | 1.06% | 7.43% | 21.34% | 26.16% | 29.24% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |